Status:
RECRUITING
Cannabinoid Hyperemesis Syndrome. Prospective Multicenter Study of Patients Admitted to Adult Emergency Departments in Maine-et-Loire.
Lead Sponsor:
University Hospital, Angers
Conditions:
D000096704
Cannabinoid Hyperemesis Syndrome
Eligibility:
All Genders
18-65 years
Brief Summary
Cannabinoid hyperemesis syndrome (CHS) is characterized by incoercible abdominal pain and vomiting in patients with chronic cannabis use. Patients are relieved by hot showers, an easily performed diag...
Eligibility Criteria
Inclusion Criteria:
- Patient aged 18 to 65 years,
- Consulted the Maine et Loire adult emergency department for abdominal pain and/or vomiting for the 1st time during the study period.
Exclusion Criteria:
- Refusal to participate in the study
- Patient unable to answer questionnaire (allophone, under guardianship, under protection, incapable of age, under legal proceedings)
- Pregnant women
Key Trial Info
Start Date :
July 25 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 31 2026
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT06660901
Start Date
July 25 2025
End Date
October 31 2026
Last Update
August 28 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Angers Centre Hospitalier Universitaire (CHU)
Angers, France, 49100
2
Centre Hospitalier de Cholet
Cholet, France, 49300
3
Centre Hospitalier de Saumur
Saumur, France, 49400